Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation

NCT00306735 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00306735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00306735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
December 31, 2007
Enrollment
75 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma